NCT06387511

Brief Summary

Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services. The investigators will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, 1) in children aged 12-23 months in the end line cross-sectional household survey, 2) in children aged 6-12 months at inclusion, in a longitudinal 12 months follow-up survey. Secondary objectives are to assess the barriers and facilitators from the perspectives of parents/legal guardian of children, health care providers and community health workers and to assess the cost-efficiency of the This study will be implemented in 20 wards covering the Karasuwa and Nguru Local Government Areas (LGAs) in Yobe state, Northeast Nigeria. This is a pragmatic parallel cluster randomized trial (PCT) with baseline measure with different populations and data collection modes: 1) baseline and end line cross-sectional household surveys of children aged 12-23 months, 2) a longitudinal follow-up survey (LS) of children aged 6-12 months at inclusion, 3) a qualitative feasibility and acceptability survey of parents of children aged 6-23 months, of health providers, of community health workers and community representatives and 4) a cost survey of parents/legal guardian of children from the longitudinal follow-up cohort, and 5) a health facility cost survey of a randomized subsample of health facilities. Clusters will be randomly allocated at a ratio of 1:1 either to the standard arm or to the NutriVax arm:

  • The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts, named the standard EPI arm;
  • The NutriVax program combining the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres (i.e. PHCCs) and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres (i.e. PHCCs) for children 6-23 months of age, named the NutriVax arm.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,814

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 23, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 29, 2024

Completed
8 days until next milestone

Study Start

First participant enrolled

May 7, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

March 10, 2026

Status Verified

March 1, 2026

Enrollment Period

1.1 years

First QC Date

April 23, 2024

Last Update Submit

March 6, 2026

Conditions

Keywords

Vaccination coverageIncentivesSmall quantity of Lipid Based Nutrients (SQ-LNS)MeaslesCost-effectivenessAcceptabilityChildAfricaNigeriaMalnutrition, prevention

Outcome Measures

Primary Outcomes (2)

  • Measles vaccine coverage in children aged 12-23 months

    The proportion of children aged 12-23 months in the endline survey who have received at least one dose of measles vaccine, as reported on their vaccination card.

    Measured after one year after of intervention implementation.

  • Measles vaccine coverage in children 6-12 months at inclusion

    The proportion of children aged 6-12 months at inclusion in the longitudinal follow-up survey, who have received at least one additional dose of measles vaccine, as reported on their vaccination card, administered between inclusion and the end of follow-up.

    Measured after one year after of intervention implementation.

Secondary Outcomes (8)

  • Measles vaccine coverage: at least one dose

    Measured after one year after of intervention implementation.

  • Measles vaccine coverage : two doses

    Measured after one year after of intervention implementation.

  • Timeliness of measles 1 vaccination

    Measured after one year after of intervention implementation.

  • Other infant vaccines coverage

    Measured after one year after of intervention implementation.

  • Zero-dose

    Measured after one year after of intervention implementation.

  • +3 more secondary outcomes

Study Arms (2)

Standard Expanded program on immunization

ACTIVE COMPARATOR

The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts.

Behavioral: Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices

NutriVax

EXPERIMENTAL

The NutriVax strategy combines the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres for children 6-23 months of age.

Dietary Supplement: Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVaxBehavioral: Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices

Interventions

1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm. 2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions. 3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward. 4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth. 5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first. 6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program.

NutriVax

1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services; 2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres; 3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages.

NutriVaxStandard Expanded program on immunization

Eligibility Criteria

Age6 Months - 23 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Aged 12-23 months;
  • With oral informed consent of parent or legal guardian;

You may not qualify if:

  • Included in the longitudinal follow-up.
  • Aged 6-12 months;
  • With written informed consent of parent or legal guardian;
  • Acute malnutrition criteria as per the WHO definition (i.e. MUAC\< 125 or WHZ \< -2 or nutritional edema);
  • \- Known medical complication that requires referral for hospitalization;
  • Known allergies to SQ-LNS or SQ-LNS contraindication;
  • Any other condition interfering with protocol adherence or the ability to give informed consent, in the judgment of the Field Investigator Sampling for HHS and LS will be carried out in three stages in each LGA using probability proportional to size (PPS).
  • Parent or legal guardian of a child aged 6-23 months and residing in the catchment settlements of wards included in the study, or Health worker of the ministry of health involved in the study,or Community representative or Community health workers;
  • With written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

All Primary Health Care Centers of Nguru and Karasuwa LGAs

Damaturu, Yobe State, Nigeria

Location

Related Publications (1)

  • Cazes C, Goni BW, Muhammad NS, Gabillard D, Balonda PK, Feuzeu L, Atanga I, Yapi B, Habiyambere GG, Danho S, Balestre E, Adams KP, Plazy M, Phelan KPQ, Becquet R. Increasing measles vaccination coverage through supplementation with an SQ-LNS incentive in children aged 6 to 23 months: study protocol of NutriVax-Measles, a superiority pragmatic parallel cluster-randomized controlled trial in Yobe State, Northern Nigeria. Trials. 2025 Nov 19;26(1):525. doi: 10.1186/s13063-025-09243-5.

Related Links

MeSH Terms

Conditions

MeaslesMalnutrition

Condition Hierarchy (Ancestors)

Morbillivirus InfectionsParamyxoviridae InfectionsMononegavirales InfectionsRNA Virus InfectionsVirus DiseasesInfectionsNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Renaud Becquet, PhD

    Institut National de la Santé Et de la Recherche Médicale, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No possible to mask intervention due to the specifity of the intervention tested
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: A two arms superiority opened pragmatic parallel cluster-randomized controlled trial with baseline measure
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 23, 2024

First Posted

April 29, 2024

Study Start

May 7, 2024

Primary Completion

June 26, 2025

Study Completion

July 30, 2025

Last Updated

March 10, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

Possible data sharing agreement, possible one year after publication of the main results.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Before (protocol, ICF) and during data collection (SAP)
Access Criteria
Protocol, ICF and SAP on clinicaltrials.gov

Locations